ALS 2
Alternative Names: ALS-2Latest Information Update: 05 Jun 2023
At a glance
- Originator The Chinese University of Hong Kong
- Developer Acticule Life Sciences
- Class Antibacterials; Small molecules
- Mechanism of Action ATP-dependent protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Methicillin-resistant Staphylococcus aureus infections; Staphylococcal infections
Most Recent Events
- 28 Apr 2023 Preclinical development for Staphylococcal infections and Methicillin-resistant Staphylococcus aureus infections is ongoing in Hong Kong
- 28 Jan 2023 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in Hong Kong
- 28 Jan 2023 No recent reports of development identified for preclinical development in Staphylococcal-infections in Hong Kong